A Phase Ib study of intermittent administration of high doses of the irreversible EGFR inhibitor afatinib as a means of achieving plasma levels active against non-small cell lung cancer with known T790M
Not available at this time
IRB Protocol #
Boehringer Ingelheim Pharmaceuticals, Inc.
TARA WELLS at (720)848-0755 or TARA.WELLS@UCDENVER.EDU
University of Colorado Hospital University of Colorado Hospital
Eligibility and Other Participant Information
What To Expect : Not available at this time // Not available at this timeNot available at this time